

Appl. No. 10/617,436

Amdt. Dated December 6, 2004

Reply to Office action of September 21, 2004


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A compound of Formula (I)



the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of said compounds, stereoisomers, and prodrugs, wherein:

W is oxygen, sulfur, -SO-, -S(O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NR^a, or -C(=CH₂)-

R¹, R², R³, and R⁶ are each independently hydrogen, halogen, -(C₁-C₈)alkyl, -CF₃, -OCF₃, -O(C₁-C₈)alkyl, or -CN;

R⁴ is hydrogen, -(C₁-C₁₂)alkyl substituted with zero to three substituents independently selected from Group V, -(C₂-C₁₂)alkenyl, -(C₂-C₁₂)alkynyl, halogen, -CN, -OR^b, -SR^c, -S(O)R^c, -S(O)₂R^c, aryl, -(C₃-C₁₀)cycloalkyl, -S(O)₂NR^cR^d, -C(O)NR^cR^d, -C(O)OR^c, -NR^aC(O)R^d, -NR^aC(O)NR^cR^d, -NR^aS(O)₂R^d, or -C(O)R^e; or

R³ and R⁴ are taken together along with the carbon atoms to which they are attached to form a carbocyclic ring of formula -(CH₂)_i- in which i is 3, 4, 5, or 6; and wherein said carbocyclic ring is substituted with zero to four substituents independently selected from -(C₁-C₄)alkyl, -OR^b, oxo, -CN, phenyl, or -NR^aR^e;

Appl. No. 10/617,436
Amdt. Dated December 6, 2004
Reply to Office action of September 21, 2004

R^5 is hydroxy, $-O(C_1-C_6)alkyl$, $-OC(O)R^f$, fluorine, or $-C(O)OR^c$;

R^a for each occurrence is independently hydrogen, or $-(C_1-C_6)alkyl$ substituted with zero or one $-(C_3-C_6)cycloalkyl$ or methoxy;

R^b for each occurrence is independently hydrogen, $-(C_1-C_{12})alkyl$ substituted with zero to three substituents independently selected from Group V, aryl, $-(C_3-C_{10})cycloalkyl$, $-C(O)NR^dR^e$, or $-C(O)R^f$;

R^c and R^d for each occurrence are each independently hydrogen, $-(C_1-C_{12})alkyl$ substituted with zero to three substituents independently selected from Group VI, $-(C_2-C_{12})alkenyl$, $-(C_2-C_{12})alkynyl$, aryl, or $-(C_3-C_{10})cycloalkyl$,

provided that when R^4 is the moiety $-SR^c$, $-S(O)R^c$, or $-S(O)_2R^c$, R^c is other than hydrogen;

R^f for each occurrence is independently $-(C_1-C_{10})alkyl$ substituted with zero to three substituents independently selected from Group VI, $-(C_2-C_{12})alkenyl$, $-(C_2-C_{10})alkynyl$, $-(C_3-C_{10})cycloalkyl$, or aryl;

R^g for each occurrence is independently hydrogen, $-(C_1-C_6)alkyl$, $-(C_2-C_6)alkenyl$, aryl, $-C(O)R^f$, $-C(O)OR^f$, $-C(O)NR^aR^f$, $-S(O)_2R^f$, or $-(C_3-C_8)cycloalkyl$;

Group V is halogen, $-CF_3$, $-OCF_3$, $-OH$, oxo, $-(C_1-C_6)alkoxy$, $-CN$, aryl, $-(C_3-C_{10})cycloalkyl$, $-SR^f$, $-S(O)R^f$, $-S(O)_2R^f$, $-S(O)_2NR^aR^f$, $-NR^aR^g$, or $-C(O)NR^aR^f$;

Group VI is halogen, hydroxy, oxo, $-(C_1-C_6)alkoxy$, aryl, $-(C_3-C_8)cycloalkyl$, $-CN$, or $-OCF_3$;

provided that when R^4 is $-(C_1-C_{12})alkyl$ substituted with zero to three substituents independently selected from Group V, wherein said Group V substituent is oxo, said oxo group is substituted on a carbon atom other than the C_1 carbon atom in $-(C_1-C_{12})alkyl$;

aryl for each occurrence is independently phenyl or naphthyl substituted with zero to four substituents independently selected from halogen, $-(C_1-C_6)alkyl$, $-CN$, $-SR^f$, $-S(O)R^f$, $-S(O)_2R^f$, $-(C_3-C_6)cycloalkyl$, $-S(O)_2NR^aR^f$, $-NR^aR^g$, $-C(O)NR^aR^f$, $-OR^b$, $-perfluoro-(C_1-C_4)alkyl$, or $-COOR^f$;


provided that when said substituent(s) on aryl are $-SR^f$, $-S(O)R^f$, $-S(O)_2R^f$, $-S(O)_2NR^aR^f$, $-NR^aR^g$, $-C(O)NR^aR^f$, $-OR^b$, or $-COOR^f$, said substituents R^b , R^f , and R^g , are other than aryl or heteroaryl;

Appl. No. 10/617,436

Amdt. Dated December 6, 2004

Reply to Office action of September 21, 2004

X is



Claim 2 (original): A compound according to claim 1 wherein W is oxygen.

Claim 3 (previously amended): A compound according to claim 1 wherein:

R^1 is located at the 3-position and R^2 is located at the 5-position, wherein R^1 and

R^2 are each independently hydrogen, $-(C_1-C_6)$ alkyl, halogen, or $-CN$;

R^3 is hydrogen, $-(C_1-C_4)$ alkyl or halogen;

R^4 is $-(C_1-C_{10})$ alkyl substituted with zero to three substituents independently selected from fluoro, hydroxy, oxo, aryl, or $-(C_3-C_8)$ cycloalkyl, $S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, $-(C_3-C_8)$ cycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$; or

R^3 and R^4 are taken together along with the carbon atoms to which they are attached to form a carbocyclic ring of formula $-(CH_2)_i-$ in which i is 3, 4, 5 or 6; and wherein said carbocyclic ring is each substituted with zero to four substituents independently selected from $-(C_1-C_4)$ alkyl, $-OR^b$, oxo, $-CN$, phenyl, or $-NR^aR^g$;


provided that when R^4 is $-(C_1-C_{10})$ alkyl substituted with zero to three substituents, said oxo group is substituted on a carbon atom other than the C_1 carbon atom in $-(C_1-C_{10})$ alkyl;

R^5 is $-OH$, $-OC(O)R^f$, $-C(O)OR^c$, or $-F$; wherein R^f is $-(C_1-C_{10})$ alkyl substituted with zero to three substituents independently selected from Group VI;

R^6 is hydrogen, halogen or $-(C_1-C_4)$ alkyl; and

X is

Appl. No. 10/617,436
 Amdt. Dated December 6, 2004
 Reply to Office action of September 21, 2004



Claim 4 (previously amended): A compound according to claim 3 wherein

R^1 and R^2 are each independently hydrogen, $-(C_1-C_6)$ alkyl, halogen, or $-CN$;

R^3 is hydrogen;

R^4 is $-(C_1-C_{10})$ alkyl substituted with zero to three substituents independently selected from fluoro, hydroxy, oxo, aryl, or $-(C_3-C_8)$ cycloalkyl, $-S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, $-(C_3-C_8)$ cycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$;

R^5 is $-OH$, fluoro, or $-OC(O)R^f$ wherein R^f is $-(C_1-C_{10})$ alkyl substituted with zero to three substituents independently selected from Group VI; and

R^6 is hydrogen.

Claim 5 (previously amended): A compound according to claim 4 wherein

R^1 and R^2 are both methyl, bromo, or chloro;

R^4 is $-(C_1-C_{10})$ alkyl, substituted with zero to two substituents independently selected from fluoro, hydroxy, oxo, aryl, or $-(C_3-C_8)$ cycloalkyl, $S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, $-(C_3-C_8)$ cycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$; and

R^5 is $-OH$.

Claim 6 (previously amended): A compound selected from the group consisting of:

2-[3,5-dichloro-4-(4-hydroxy-3-isopropyl-phenoxy)-benzyl]-
 [1,2,4]oxadiazolidine-3,5-dione;

Appl. No. 10/617,436
Amdt. Dated December 6, 2004
Reply to Office action of September 21, 2004

2-[4-(3-isopropyl-4-methoxy-phenoxy)-3,5-dimethyl-benzyl]-
[1,2,4]oxadiazolidine-3,5-dione; and;

2-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-benzyl]-
[1,2,4]oxadiazolidine-3,5-dione;

the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts
of said compounds, stereoisomers, and prodrugs.

Claims 7-17 (previously cancelled)

Claim18 (original): A pharmaceutical composition comprising a compound of Formula
(I), a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said
compound, stereoisomer or prodrug, as defined in claim 1.

Claims 19-25 (previously cancelled)

Claims 26 and 27 (cancelled)